Ratings MacroGenics, Inc.

Equities

MGNX

US5560991094

Real-time Estimate Cboe BZX Other stock markets 12:10:11 2024-04-25 pm EDT			5-day change	1st Jan Change
14.46 ^USD	-7.93%		-8.81%	+52.34%

Apr. 10	North American Morning Briefing : Traders Await -2-	DJ
Apr. 09	TD Cowen Upgrades MacroGenics to Buy From Hold	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MACROGENICS, INC.	+63.20%	982M	C+
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B	B+
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B	B+
ARGENX SE	+0.76%	22.2B	B
BIONTECH SE	-16.53%	21.23B	B+
GENMAB A/S	-8.33%	18.33B	A-
WUXI APPTEC CO., LTD.	-42.33%	16.35B	A-
BEIGENE, LTD.	-20.09%	15.06B	B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B	C+
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes